Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT06545942. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.
Study identification
- NCT ID
- NCT06545942
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 220 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 12, 2024
- Primary completion
- May 30, 2027
- Completion
- Nov 29, 2027
- Last update posted
- Jul 22, 2026
2024 – 2027
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site #108 | Goodyear | Arizona | 85338 | Recruiting |
| Investigative Site #101 | La Jolla | California | 92093 | Recruiting |
| Investigative Site #111 | San Francisco | California | 94143 | Completed |
| Investigative Site #104 | Lake Mary | Florida | 32746 | Recruiting |
| Investigative Site #110 | St Louis | Missouri | 63110 | Recruiting |
| Investigative Site #103 | New York | New York | 10016 | Recruiting |
| Investigative Site #106 | New York | New York | 10065 | Recruiting |
| Investigative Site #109 | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Investigative Site #107 | Myrtle Beach | South Carolina | 29572 | Completed |
| Investigative Site #102 | Nashville | Tennessee | 37203 | Recruiting |
| Investigative Site #105 | San Antonio | Texas | 78229 | Completed |
| Investigative Site #112 | Fairfax | Virginia | 22031 | Completed |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06545942, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06545942 live on ClinicalTrials.gov.